135 related articles for article (PubMed ID: 27120117)
1. Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress.
Kim JH; Kim E; Choi WH; Lee J; Lee JH; Lee H; Kim DE; Suh YH; Lee MJ
Mol Pharm; 2016 Jun; 13(6):2039-48. PubMed ID: 27120117
[TBL] [Abstract][Full Text] [Related]
2. Functional Selection of Tau Oligomerization-Inhibiting Aptamers.
Wang B; Pan X; Teng IT; Li X; Kobeissy F; Wu ZY; Zhu J; Cai G; Yan H; Yan X; Liang M; Yu F; Lu J; Yang Z; Biondi E; Haskins W; Cao YC; Benner SA; Tan W; Wang KK
Angew Chem Int Ed Engl; 2024 Apr; 63(18):e202402007. PubMed ID: 38407551
[TBL] [Abstract][Full Text] [Related]
3. Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo.
Violet M; Chauderlier A; Delattre L; Tardivel M; Chouala MS; Sultan A; Marciniak E; Humez S; Binder L; Kayed R; Lefebvre B; Bonnefoy E; Buée L; Galas MC
Neurobiol Dis; 2015 Oct; 82():540-551. PubMed ID: 26385829
[TBL] [Abstract][Full Text] [Related]
4. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
5. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity.
Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
Neurodegener Dis; 2017; 17(2-3):73-82. PubMed ID: 27760426
[TBL] [Abstract][Full Text] [Related]
6. Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons.
Si Z; Wang X; Zhang Z; Wang J; Li J; Li J; Li L; Li Y; Peng Y; Sun C; Hui Y; Gao X
J Alzheimers Dis; 2018; 65(2):409-419. PubMed ID: 30040734
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
[TBL] [Abstract][Full Text] [Related]
8. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
Wagner J; Krauss S; Shi S; Ryazanov S; Steffen J; Miklitz C; Leonov A; Kleinknecht A; Göricke B; Weishaupt JH; Weckbecker D; Reiner AM; Zinth W; Levin J; Ehninger D; Remy S; Kretzschmar HA; Griesinger C; Giese A; Fuhrmann M
Acta Neuropathol; 2015 Nov; 130(5):619-31. PubMed ID: 26439832
[TBL] [Abstract][Full Text] [Related]
9. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein.
Teng IT; Li X; Yadikar HA; Yang Z; Li L; Lyu Y; Pan X; Wang KK; Tan W
J Am Chem Soc; 2018 Oct; 140(43):14314-14323. PubMed ID: 30277395
[TBL] [Abstract][Full Text] [Related]
11. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
12. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
[TBL] [Abstract][Full Text] [Related]
13. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.
Kondo A; Shahpasand K; Mannix R; Qiu J; Moncaster J; Chen CH; Yao Y; Lin YM; Driver JA; Sun Y; Wei S; Luo ML; Albayram O; Huang P; Rotenberg A; Ryo A; Goldstein LE; Pascual-Leone A; McKee AC; Meehan W; Zhou XZ; Lu KP
Nature; 2015 Jul; 523(7561):431-436. PubMed ID: 26176913
[TBL] [Abstract][Full Text] [Related]
14. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.
Avila J; Pallas N; Bolós M; Sayas CL; Hernandez F
Expert Opin Ther Targets; 2016 Jun; 20(6):653-61. PubMed ID: 26652296
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
[TBL] [Abstract][Full Text] [Related]
16. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
Jouanne M; Rault S; Voisin-Chiret AS
Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
[TBL] [Abstract][Full Text] [Related]
17. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
Rickard JE; Horsley D; Wischik CM; Harrington CR
Methods Mol Biol; 2017; 1523():129-140. PubMed ID: 27975248
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau
Lim S; Shin S; Sung Y; Lee HE; Kim KH; Song JY; Lee GH; Aziz H; Lukianenko N; Kang DM; Boesen N; Jeong H; Abdildinova A; Lee J; Yu BY; Lim SM; Lee JS; Ryu H; Pae AN; Kim YK
Exp Mol Med; 2023 Mar; 55(3):612-627. PubMed ID: 36914856
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
20. A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.
Sun H; Zhong Y; Zhu X; Liao H; Lee J; Chen Y; Ma L; Ren J; Zhao M; Tu M; Li F; Zhang H; Tian M; Ling D
ACS Nano; 2021 Mar; 15(3):5263-5275. PubMed ID: 33683854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
